GlassScriptPhysician profile
Joseph A Cinderella
NPI 1407848609
$71,555.93
in general payments reported to CMS, 2019-2025
39 companies · $7,051 in 2025
The $7,051 reported for 2025 was more than what 86% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2020: $943 · 2021: $17K · 2022: $9,280 · 2023: $14K · 2024: $21K · 2025: $7,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $5,980 · Travel and Lodging: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,868.75 |
| Food and Beverage | $5,980.10 |
| Travel and Lodging | $1,511.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41,310.33 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $20,420.14 | 2021-2025 | Jardiance |
| Medtronic, INC. | $1,539.10 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Ffrangio |
| Abbott Laboratories | $901.05 | 2019-2025 | Mitraclip, Xience Skypoint, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic Vascular, INC. | $831.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $830.54 | 2019-2025 | Leqvio |
| Boston Scientific Corporation | $748.81 | 2019-2025 | Watchman Flx, Farapulse, Watchman |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $642.13 | 2019-2025 | Lifevest |
| Amgen INC. | $637.89 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $632.55 | 2019-2023 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $476.28 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $375.26 | 2019-2025 | |
| Scpharmaceuticals INC. | $332.12 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $238.41 | 2023-2024 | Inpefa |
| Chiesi USA, INC. | $228.75 | 2019-2023 | Cleviprex, Kengreal |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cinderella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.